Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8+ T cells

Journal for ImmunoTherapy of Cancer

Volumn 2, Issue 1, 2014, Pages

  Pollack, Seth M ^a,b   Jones, Robin L ^a,b   Farrar, Erik A ^a   Lai, Ivy P ^a,e   Lee, Sylvia M ^a,b   Cao, Jianhong ^a   Pillarisetty, Venu G ^a,c   Hoch, Benjamin L ^b   Gullett, Ashley ^b   Bleakley, Marie ^a,c   Conrad, Ernest U ^b   Eary, Janet F ^d   Shibuya, Kendall C ^a   Warren, Edus H ^a,b   Carstens, Jason N ^a   Heimfeld, Shelly ^a   Riddell, Stanley R ^a,b,e   Yee, Cassian ^a,b,f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d University of Alabama at Birmingham   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adoptive T cell therapy; Antigen specific T cells; Immunotherapy; Influx cell sorting; Liposarcoma; Myxoid; NY ESO 1; Synovial sarcoma; Tetramer

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD45RO ANTIGEN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GLYCOPROTEIN GP 100; IFOSFAMIDE; NY ESO 1 ANTIGEN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TETRAMER;

ADULT; ARTICLE; BINDING AFFINITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL THERAPY; CLINICAL ARTICLE; CLONAL VARIATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA SEQUENCE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKAPHERESIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; MIDDLE AGED; MYXOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNOVIAL SARCOMA; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL LINE;

EID: 84977074161     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-014-0036-y     Document Type: Article

References (37)

1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281. 10.1038/nri3191, 22437939.
2. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012, 109(12):4592-4597. doi: 10.1073/pnas.1113748109. Epub 2012 Mar 5, 10.1073/pnas.1113748109, 22393002.
3. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee C. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008, 358:2698-2703. 10.1056/NEJMoa0800251, 18565862.
4. Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther 2007, 15:825-833. 17299405.
5. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011, 29(7):917-924. doi: 10.1200/JCO.2010.32.2537. Epub 2011 Jan 31, 10.1200/JCO.2010.32.2537, 21282551.
6. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011, 365:725-733. 10.1056/NEJMoa1103849, 21830940.
7. Brentjens RJ, Davila ML, Riviere I, Park J, Wang X, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu J, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M, Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013, 5(177):177ra138. doi: 10.1126/scitranslmed.3005930., 10.1126/scitranslmed.3005930.
8. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother 2013, 36(2):133-151. doi: 10.1097/CJI.0b013e3182829903, 10.1097/CJI.0b013e3182829903, 23377668.
9. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129. Epub 2006 Aug 31, 10.1126/science.1129003, 16946036.
10. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011, 3:95ra73. 10.1126/scitranslmed.3002842, 21832238.
11. Bendle GM, Linnemann C, Hooijkaas AI, Bies L, de Witte MA, Jorritsma A, Kaiser AD, Pouw N, Debets R, Kieback E, Uckert W, Song JY, Haanen JB, Schumacher TN. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med 2010, 16(5):565-570. 1p following 570. doi: 10.1038/nm.2128. Epub 2010 Apr 18, 10.1038/nm.2128, 20400962.
12. Coccoris M, Straetemans T, Govers C, Lamers C, Sleijfer S, Debets R. T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies. Expert Opin Biol Ther 2010, 10:547-562. 10.1517/14712591003614756, 20146634.
13. Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002, 99:16168-16173. 10.1073/pnas.242600099, 12427970.
14. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imataki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med 2011, 3(80):80ra34. doi: 10.1126/scitranslmed.3002207, 10.1126/scitranslmed.3002207, 21525398.
15. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, Vieweg J. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005, 115:3623-3633. 10.1172/JCI25947, 16308572.
16. Attia P, Powell DJ, Maker AV, Kreitman RJ, Pastan I, Rosenberg SA. Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2. J Immunother 2006, 29:208-214. 10.1097/01.cji.0000187959.45803.0c, 16531821.
17. Rasmussen AM, Borelli G, Hoel HJ, Lislerud K, Gaudernack G, Kvalheim G, Aarvak T. Ex vivo expansion protocol for human tumor specific T cells for adoptive T cell therapy. J Immunol Methods 2010, 355:52-60. 10.1016/j.jim.2010.02.004, 20171968.
18. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 2008, 111:229-235. 10.1182/blood-2007-05-089375, 17921346.
19. Li Y, Bleakley M, Yee C. IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol 2005, 175:2261-2269. 10.4049/jimmunol.175.4.2261, 16081794.
20. Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer 2012, 118(18):4564-4570. doi: 10.1002/cncr.27446. Epub 2012 Feb 22, 10.1002/cncr.27446, 22359263.
21. Jungbluth AA, Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, Chen YT, Stockert E, Ladanyi M, Old LJ. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int J Cancer 2001, 94:252-256. 10.1002/ijc.1451, 11668506.
22. Singer S, Baldini EH, Demetri GD, Fletcher JA, Corson JM. Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival. J Clin Oncol 1996, 14:1201-1208. 8648375.
23. Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee C. NYESO-1/LAGE-1s and PRAME Are targets for antigen specific t cells in chondrosarcoma following treatment with 5-Aza-2-Deoxycitabine. PLoS One 2012, 7(2):e32165. doi: 10.1371/journal.pone.0032165. Epub 2012 Feb 27, 10.1371/journal.pone.0032165, 22384167.
24. Neudorfer J, Schmidt B, Huster KM, Anderl F, Schiemann M, Holzapfel G, Schmidt T, Germeroth L, Wagner H, Peschel C, Busch DH, Bernhard H. Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens. J Immunol Methods 2007, 320(1-2):119-131. Epub 2007 Jan 31, 10.1016/j.jim.2007.01.001, 17306825.
25. Wang X, Schmitt A, Chen B, Xu X, Mani J, Linnebacher M, Freund M, Schmitt M. Streptamer-based selection of WT1-specific CD8+ T cells for specific donor lymphocyte infusions. Exp Hematol 2010, 38:1066-1073. 10.1016/j.exphem.2010.07.002, 20637829.
26. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, Feldman SA, Johnson LA, Bennett AD, Dunn SM, Mahon TM, Jakobsen BK, Rosenberg SA. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008, 180(9):6116-6131. 10.4049/jimmunol.180.9.6116, 18424733.
27. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH. Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanoma. Blood 2013, 122(6):863-871. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14, 10.1182/blood-2013-03-490565, 23770775.
28. Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, Wlfl M, Bar M, Radich JP, Yee C, Greenberg PD. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013, 5(174):174ra27. doi: 10.1126/scitranslmed.3004916, 10.1126/scitranslmed.3004916, 23447018.
29. Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, Yee C, Nghiem P. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res 2014, 2(1):27-36. doi: 10.1158/2326-6066.CIR-13-0087, 10.1158/2326-6066.CIR-13-0087, 24432305.
30. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, Bleakley M, Greenberg PD. Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 2007, 110:201-210. 10.1182/blood-2006-11-056168, 17371945.
31. Ayyoub M, Pignon P, Classe JM, Odunsi K, Valmori D. CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with, but are distinct from, tumor-associated Treg. Cancer Immunol Res 2013, 1:303-308. 10.1158/2326-6066.CIR-13-0062-T, 24777968.
32. Yang J, James EA, Huston L, Danke NA, Liu AW, Kwok WW. Multiplex mapping of CD4 T cell epitopes using class II tetramers. Clin Immunol 2006, 120:21-32. 10.1016/j.clim.2006.03.008, 16677863.
33. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996, 196:121-135. 10.1016/0022-1759(96)00079-8, 8841451.
34. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990, 128:189-201. 10.1016/0022-1759(90)90210-M, 1691237.
35. Kawai A, Naito N, Yoshida A, Morimoto Y, Ouchida M, Shimizu K, Beppu Y. Establishment and characterization of a biphasic synovial sarcoma cell line, SYO-1. Cancer Lett 2004, 204:105-113. 10.1016/j.canlet.2003.09.031, 14744540.
36. Aman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K, Willen H, Rydholm A, Mitelman F. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes Chromosomes Cancer 1992, 5:278-285. 10.1002/gcc.2870050403, 1283316.
37. Akatsuka Y, Martin EG, Madonik A, Barsoukov AA, Hansen JA. Rapid screening of T-cell receptor (TCR) variable gene usage by multiplex PCR: application for assessment of clonal composition. Tissue Antigens 1999, 53:122-134. 10.1034/j.1399-0039.1999.530202.x, 10090612.